Clinical Trials Directory

Trials / Completed

CompletedNCT00192166

Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months

Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
1,200 (planned)
Sponsor
MedImmune LLC · Industry
Sex
All
Age
11 Months – 24 Months
Healthy volunteers
Accepted

Summary

\- The primary objective of the study was to determine if intranasally administered influenza virus vaccine, CAIV-T), when administered concomitantly with a subcutaneously administered combination live, attenuated mumps, measles, and rubella (MMR) virus vaccine to children interferes with the immune responses.

Detailed description

* The primary objective of the study was to determine if intranasally administered influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T), when administered concomitantly with a subcutaneously administered combination live, attenuated mumps, measles, and rubella (MMR) virus vaccine to children aged 11 to less than 24 months, interferes with the immune responses to the measles, mumps, and rubella components of the MMR vaccine. * To compare the efficacy over one season against culture-confirmed influenza-illness caused by community-acquired subtypes antigenically similar to those contained in the vaccine, in children who are aged at least 11 months and less than 24 months at enrollment, between those who receive two doses of CAIV-T and those who receive placebo, each with concomitant administration of a combination live, attenuated MMR vaccine administered prior to the anticipated commencement of the influenza season.

Conditions

Interventions

TypeNameDescription
BIOLOGICALCAIV-T

Timeline

Start date
2002-10-01
Primary completion
2003-03-01
Completion
2003-05-01
First posted
2005-09-19
Last updated
2008-12-08

Locations

1 site across 1 country: Singapore

Source: ClinicalTrials.gov record NCT00192166. Inclusion in this directory is not an endorsement.